Vytrus Biotech, a Catalan biotechnology firm that works in plant stem-cell cultures and the production of active ingredients for the pharmaceutical and cosmetic sectors, is celebrating its tenth anniversary. This comes at a time of growth for the company, which expects to go public in late 2020. Newspaper El Periódico published a report on the company, with the title The Year of Vytrus Biotech (in Spanish).

Over the past three years, Vytrus’ sales have seen over 30% growth thanks to nine products on the market and distribution deals in 54 countries. The firm has 22 professionals on staff (35% in R&D) and a 900-square-metre premises in Terrassa (Barcelona).

Vytrus was created as a spin-off of the University of Barcelona Faculty of Pharmacy and is a member of CataloniaBio & HealthTech along with more than 160 innovative companies working in the life sciences arena in Catalonia. 

You may also be interested in:

• The new ICF Venture Tech II fund invests €0.5 million in Vytrus Biotech
• Vytrus Biotech triumphs at top international cosmetics event